BioSpace News Archive

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022.

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company’s Cannabis market entry strategy into North America.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $2 million grant to be awarded to the Advanced Cardiac Therapies Improving Outcomes Network (ACTION), a learning health system focused on children and adult congenital heart disease patients at risk of heart dysfunction or with heart failure.

Stryker, a leading medical technologies company, attended the 6th World Intelligence Congress in China, showcasing how its Advanced Digital Healthcare solutions brings clinical, operational and financial values for the healthcare market.

Forecast to 2030,’ thoroughly examines the Ferric Citrate industry to provide essential data & information for the targeted readers.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services (“HHS”) and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento’s Chairman and CEO Henry Ji. Governor Thompson’s appointment is effective immediately.

Hepion Pharmaceuticals, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Friday, July 22, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4, as described in Hepion’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 19, 2022.

Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022.

Veru Inc., a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, announced the granting of inducement awards to three new employees.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi®.